Figures & data
Figure 1. (a) UV–Visible spectra of pectin-reduced gold nanoparticles. (b) HRTEM images recorded of as synthesized pectin-reduced gold nanoparticles. (c) XRD patterns of as synthesized gold nanoparticles.
Figure 2. (a) UV–Visible spectra of supernatant and redispersed pellet of doxorubicin-loaded pectin-capped gold nanoparticles. (b) UV–Visible absorption spectra of DOX-loaded PEC-AuNPs. (c,d) HRTEM images captured of DOX-loaded PEC-AuNPs.
Figure 3. FTIR spectra of (a) doxorubicin and (b) doxorubicin-loaded PEC-AuNPs.
Figure 4. (a) Effect of pH, ionic strength and storage stability on DOX-PEC-AuNPs and (b) DOX content in formulation after 3 months of storage at 4 °C.
Figure 5. In vitro DOX release behaviors of DOX-loaded AuNPs in phosphate buffer (pH 7.4) and acetate buffer (pH 5).
Figure 6. Viability of (a) HepG2 (b) HeLa cells after 48 h of exposure to (from left to right): control, blank gold nanoparticles, DOX solution and DOX-loaded PEC-AuNPs.
Figure 7. Influence of inhibitors on the internalization of PEC-AuNPs by HepG2 cells.
Figure 8. Intracellular amount of DOX in (A) HepG2 and (B) HeLa cells after incubating with DOX-PEC-AuNPs in (a) absence of galactose (b) presence of 65 mM/L of galactose at 37 °C.
Figure 9. Intracellular amount of gold in HepG2 and HeLa cells after incubation in absence and presence of 65 mM/L of galactose at 37 °C.
Figure 10. Confocal microscopy images of HepG2 cells when treated (a) Control, (b) DOX, (c) DOX-loaded PEC-AuNPs and (d) DOX-loaded PEC-AuNPs in presence of 65 mM/L galactose.
